115 related articles for article (PubMed ID: 36382849)
21. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
[TBL] [Abstract][Full Text] [Related]
22. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
[TBL] [Abstract][Full Text] [Related]
23. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
[TBL] [Abstract][Full Text] [Related]
24. Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study.
Tehranchi R; Pettersson J; Melgaard AE; Seitz F; Valeur A; Maarbjerg SJ
Curr Ther Res Clin Exp; 2022; 96():100668. PubMed ID: 35464292
[TBL] [Abstract][Full Text] [Related]
25. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
26. Lack of an Effect of Supratherapeutic Dose of Venlafaxine on Cardiac Repolarization in Healthy Subjects.
Abbas R; Riley S; Nepal S; Bachinsky M; Lee KC; Chappell PB; Damle B
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):100-111. PubMed ID: 34242472
[TBL] [Abstract][Full Text] [Related]
27. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
28. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Valade E; Dosne AG; Xie H; Kleiman R; Li LY; Perez-Ruixo JJ; Ouellet D
Cancer Chemother Pharmacol; 2019 Sep; 84(3):621-633. PubMed ID: 31280362
[TBL] [Abstract][Full Text] [Related]
30. Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study.
Kim S; Lee H; Ko JW; Kim JR
Clin Ther; 2019 Nov; 41(11):2204-2218. PubMed ID: 31564512
[TBL] [Abstract][Full Text] [Related]
31. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
32. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.
Moore K; Infante JR; Cotreau MM; Wilson L; Strahs AL; Vargo DL; Chadha M
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):284-9. PubMed ID: 27128834
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors.
Zhou X; Diderichsen PM; Gupta N
Clin Pharmacol Drug Dev; 2022 Jun; 11(6):770-779. PubMed ID: 35187855
[TBL] [Abstract][Full Text] [Related]
34. Metabolism and Disposition of [
Bolleddula J; Chen H; Cohen L; Zhou X; Pusalkar S; Berger A; Sedarati F; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2022 Jul; 50(7):989-997. PubMed ID: 35504658
[TBL] [Abstract][Full Text] [Related]
35. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
[TBL] [Abstract][Full Text] [Related]
36. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
[TBL] [Abstract][Full Text] [Related]
37. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
38. A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
Sahota T; Dota CD; Vik T; Yan W; Verheijen RB; Walker S; Li Y; Goldwater R; Ghiorghiu D; Mellemgaard A; Ahmed GF
Clin Pharmacol Drug Dev; 2021 May; 10(5):521-534. PubMed ID: 33400845
[TBL] [Abstract][Full Text] [Related]
39. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
[TBL] [Abstract][Full Text] [Related]
40. Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations.
Trivedi A; Hsu CP; Jafarinasabian P; Terminello B; Zhang H; Flach S; Israel S; Brooks A; Xue H; Darpo B; Abbasi S; Dutta S; Lee E
Br J Clin Pharmacol; 2022 Jan; 88(1):187-198. PubMed ID: 34131942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
